Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 X CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

被引：12

作者：

Rutella, Sergio ^{[1
]}

Church, Sarah E. ^{[2
]}

Vadakekolathu, Jayakumar ^{[1
]}

Viboch, Elena ^{[2
]}

Sullivan, Amy H. ^{[2
]}

Hood, Tressa ^{[2
]}

Warren, Sarah E. ^{[2
]}

Cesano, Alessandra ^{[2
]}

La Motte-Mohs, Ross ^{[3
]}

Muth, John ^{[3
]}

Lelievre, Helene ^{[4
]}

Lowenberg, Bob ^{[5
]}

DiPersio, John F. ^{[6
]}

Davidson-Moncada, Jan K. ^{[3
]}

机构：

[1] Nottingham Trent Univ, John van Geest Canc Res Ctr, Nottingham, England

[2] NanoString Technol Inc, Seattle, WA USA

[3] MacroGenics Inc, Rockville, MD USA

[4] Servier, Ctr Rech Cancerol Marseille, Suresnes, France

[5] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands

[6] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111539

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

444

引用

页数：3

共 50 条

[1] Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Uy, Geoffrey L.
Aldoss, Ibrahim
Foster, Matthew C.
Sallman, David A.
Sweet, Kendra L.
Rizzieri, David A.
Sayre, Peter H.
Advani, Anjali S.
Emadi, Ashkan
Wieduwilt, Matthew J.
Vey, Norbert
Ciceri, Fabio
Carrabba, Matteo Giovanni
Moyo, Tamara
Church, Sarah E.
Rettig, Michael P.
Arellano, Martha L.
Godwin, John E.
Lowenberg, Bob
Huls, Gerwin
Ravandi, Farhad
Muth, John
Tran, Kathy
Jongen-Lavrencic, Mojca
Timmeny, Erin
Topp, Max S.
Paolini, Stefania
Guo, Kuo
Curtis, Teia
Zhao, Jian
Vadakekolathu, Jayakumar
Wigginton, Jon M.
Bonvini, Ezio
Rutella, Sergio
Walter, Roland B.
Davidson-Moncada, Jan K.
DiPersio, John F.
BLOOD, 2019, 134
[2] Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Uy, Geoffrey L.
Godwin, John
Rettig, Michael P.
Vey, Norbert
Foster, Matthew
Arellano, Martha L.
Rizzieri, David A.
Topp, Max S.
Huls, Gerwin
Lowenberg, Bob
Martinelli, Giovanni
Paolini, Stefania
Ciceri, Fabio
Carrabba, Matteo Giovanni
Ballesteros-Merino, Carmen
Bifulco, Carlo B.
Lelievre, Helene
La Motte-Mohs, Ross
Li, Daner
Sun, Jichao
Jacobs, Kenneth
Spohn, Karen
Lonsdale, Nadia
Tran, Kathy
Baughman, Jan
Shannon, Michele
Fox, Bernard
Bonvini, Ezio
Wigginton, Jon
Davidson-Moncada, Jan
DiPersio, John F.
BLOOD, 2017, 130
[3] Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123xCD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia
Vadakekolathu, Jayakumar
Yau, Tung On
Church, Sarah E.
Rettig, Michael P.
Aldoss, Ibrahim
Uy, Geoffrey L.
Vey, Norbert
Emadi, Ashkan
Sayre, Peter H.
Walter, Roland B.
Foster, Matthew C.
Arellano, Martha L.
Godwin, John E.
Wieduwilt, Matthew J.
Byrne, Michael T.
Michaelis, Laura C.
Stiff, Patrick J.
Carrabba, Matteo Giovanni
Chevalier, Patrice
Gyan, Emmanuel
Recher, Christian
Advani, Anjali S.
Wermke, Martin
Erba, Harry P.
Ciceri, Fabio
Huls, Geert
Jongen-Lavrencic, Mojca
Ravandi, Farhad
Curti, Antonio
Topp, Max S.
Muth, John
Kaminker, Patrick
Lowenberg, Bob
Gojo, Ivana
Luznik, Leo
DiPersio, John F.
Davidson-Moncada, Jan K.
Rutella, Sergio
BLOOD, 2020, 136
[4] A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Wei, Andrew H.
Fong, Chun Yew
Montesinos, Pau
Calbacho, Maria
Gil, Jordi Sierra
Perez De Oteyza, Jaime
Rowe, Jacob M.
Wolach, Ofir
Ofran, Yishai
Moshe, Yakir
Sun, Jichao
Baughman, Jan
McNulty, Eileen
Bonvini, Ezio
Wigginton, Jon M.
Davidson-Moncada, Jan K.
BLOOD, 2019, 134
[5] Phase 1 Cohort Expansion of Flotetuzumab, a CD123xCD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Uy, Geoffrey L.
Rettig, Michael P.
Vey, Norbert
Godwin, John
Foster, Matthew C.
Rizzieri, David A.
Arellano, Martha L.
Topp, Max S.
Huls, Gerwin
Jongen-Lavrencic, Mojca
Martinelli, Giovanni
Paolini, Stefania
Ciceri, Fabio
Carrabba, Matteo Giovanni
Sweet, Kendra L.
Ravandi, Farhad
Church, Sarah E.
Vadakekolathu, Jayakumar
Rutella, Sergio
Sun, Jichao
Yang, Kang
Baughman, Jan
Curtis, Teia
Timmeny, Erin
Cali, Kerri
Tran, Kathy
Muth, John
La Motte-Mohs, Ross
Poirot, Camille
Pallis, Athanasios
Cesano, Alessandra
Bonvini, Ezio
Wigginton, Jon
Lowenberg, Bob
Davidson-Moncada, Jan K.
DiPersio, John F.
BLOOD, 2018, 132
[6] Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123xCD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Vadakekolathu, Jayakumar
Minden, Mark D.
Hood, Tressa
Church, Sarah E.
Reeder, Stephen
Altmann, Heidi
Sullivan, Amy H.
Viboch, Elena J.
Patel, Tasleema
Ibrahimova, Narmin
Warren, Sarah E.
Arruda, Andrea
Schmitz, Marc
Liang, Yan
Cesano, Alessandra
Pockley, A. Graham
Valk, Peter
Lowenberg, Bob
Bornhauser, Martin
Tasian, Sarah K.
Rettig, Michael P.
Davidson-Moncada, Jan K.
DiPersio, John F.
Rutella, Sergio
BLOOD, 2019, 134
[7] Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
Jacobs, Kenneth
Viero, Cedric
Godwin, John
Baughman, Jan
Sun, Jichao
Ying, Kang
Muth, John
Hong, Shengyan
Vey, Norbert
Sweet, Kendra L.
Uy, Geoffrey L.
Ravandi, Farhad
Foster, Matthew C.
Rizzieri, David A.
Arellano, Martha L.
Rettig, Michael P.
Topp, Max S.
Huls, Gerwin
Lelievre, Helene
Paolini, Stefania
Ciceri, Fabio
Carrabba, Matteo Giovanni
Lowenberg, Bob
DiPersio, John F.
Wigginton, Jon
Davidson-Moncada, Jan K.
BLOOD, 2018, 132
[8] Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS
Vey, N.
Davidson-Moncada, J.
Uy, G. L.
Foster, M.
Rizzieri, D.
Godwin, J.
Topp, M.
Ciceri, F.
Carrabba, M.
Martinelli, G.
Huls, G. A.
Wegener, A.
Shannon, M.
Tran, K.
Sun, J.
Bonvini, E.
Lowenberg, B.
Wigginton, J.
Dipersio, J. F.
ANNALS OF ONCOLOGY, 2017, 28
[9] Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
Bakkacha, Ouiam
Uy, Geoffrey L.
Aldoss, Ibrahim
Foster, Matthew C.
Sallman, David A.
Sweet, Kendra L.
Rizzieri, David A.
Sayre, Peter H.
Advani, Anjali S.
Emadi, Ashkan
Wieduwilt, Matthew J.
Vey, Norbert
Ciceri, Fabio
Carrabba, Matteo Giovanni
Moyo, Tamara
Arellano, Martha L.
Godwin, John E.
Lowenberg, Bob
Huls, Gerwin
Ravandi, Farhad
Tran, Kathy
Muth, John
Baughman, Jan
Jongen-Lavrencic, Mojca
Timmeny, Erin
Topp, Max S.
Paolini, Stefania
Guo, Kuo
Curtis, Teia
Zhao, Jian
Wigginton, Jon
Bonvini, Ezio
Walter, Roland B.
Davidson, Jan
DiPersio, John F.
Jacobs, Kenneth
BLOOD, 2019, 134
[10] A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies
Winer, Eric S.
Maris, Michael
Sharma, Manish R.
Kaminker, Patrick
Zhao, Enxu
Ward, Ashley
Sochacki, Andrew L.
BLOOD, 2022, 140 : 11753 - 11754

← 1 2 3 4 5 →